Hi imback,
thank you for the two links. Exactly what we urgently need! I agree with you, the Chinese study with 600 people could make the difference for a2m in all Asian markets. Close cooperation with Chinese specialists in human medicine and nutrition is the corner stone for "our" company. Anxiously waiting for the final results. I still get crazy about the potential market in China, when a few 100 mio people start with milk again.
The autism trial is a must and I am happy that a university is sponsering the project. They might have a big advantage if their "risk capital" supports a link between A1 and autism.
Great news
2 new studies from A2MC, page-2
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.92 |
Change
0.110(2.29%) |
Mkt cap ! $3.562B | |||
| Open | High | Low | Value | Volume |
| $4.82 | $4.94 | $4.79 | $10.09M | 2.061M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $4.89 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.92 | 23558 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| A2M (ASX) Chart |